Institutional investors snap up discounted Hapvida bonds - Valor International
With Hapvida debentures and real estate receivables certificates (CRIs) under heavy pressure in the secondary market, institutional investors have stepped in to buy the securities. According to sources familiar with the matter who spoke to Valor, buyers included BTG Pactual, Lumina, Farallon, and equity funds managed by SPX Capital and Atmos. Industry sources said the transaction volume ranged from R$3 billion to R$5 billion. The institutions declined to comment.
A survey by Vitrify shows that R$4.3 billion in these two types of securities changed hands in November. Of that amount, roughly 70% was bought by new asset managers from outside the existing investor group. The November volume was more than twice October’s. “In November, debentures traded at discounts of up to 40%, while CRIs were discounted by 24%. That is well above the depreciation seen in the secondary market. There is a Hapvida-specific factor here; it is not just a macroeconomic issue,” said Daniel Magalhães, co-founder of Vitrify.
The profile of some of the buyers, including Lumina, Farallon, and BTG, is noteworthy. They are known for investing in companies under restructuring. Sources say that is not the case with Hapvida, and that the bet is on an operational turnaround.
One asset manager described Hapvida as a “good investment,” saying management is doing an efficient job and could deliver results in 2027 and 2028. The healthcare operator has also used cash to buy back part of its debt, most recently repurchasing a total of R$185 million. “We are buying back debt; there is a substantial discount,” Hapvida CEO Lucas Adib said during a conference call with analysts and investors last week.
“The company has issuances with very different maturities, and the longer-dated securities fell as low as 50% of face value, reflecting a high level of risk,” said Sérgio Omati, product director at the Credit Guide platform. In his view, there is no risk of an immediate default event. He added that the company has no liquidity problems, has cash on hand, and continues to meet its principal repayment obligations. “But investors are concerned about solvency.”
Omati said the healthcare operator has been reporting low profitability, and its estimated operating cash flow is not enough to cover debt servicing over time. A recovery in margins would be necessary. The medical loss ratio has remained high, and Hapvida is also facing lawsuits from customers, which require the company to increase provisions for additional losses.
Omati said the bond maturing in 2027 traded at less than R$1 million per day through October 29, at around 97% of face value. From October 30 to November 10, large blocks changed hands at roughly 60% of face value. He noted that on two of those days the minimum, average, and maximum prices were identical, suggesting the prices had been agreed off-screen. On November 10 alone, one-third of the issuance changed hands. Over nine trading sessions, trading volume reached R$379 million, equivalent to one and a half times the entire issuance. On November 11 and 12, when Hapvida released its results, transactions were already taking place at 72% and 75% of face value, respectively.
“Someone sold an 11-month bond at a steep discount, and someone else bought it and watched its price rise by 15 percentage points in two trading sessions. This behavior is more consistent with a buyer who saw value than with someone exiting because of bad information,” Omati said.
Hapvida ended the third quarter with R$5.1 billion in unrestricted cash. The company has R$12 billion in debentures and CRIs outstanding, with the largest portion of its liabilities, R$4.3 billion, maturing in 2032. Its leverage ratio stands at 1.67 times earnings before interest, taxes, depreciation, and amortization (EBITDA).
“The company has enough cash to pay its debt. The problem there is management. In addition, it is selling assets, which could help. A restructuring is underway,” said an asset manager who bought the company’s debentures.
Regulations require healthcare companies to maintain a certain level of liquidity to cover claims arising from the health plans they sell. “When you look at total cash, the amount is substantial, but not all of it can be used to pay down debt,” said Omati of Credit Guide.
In October, Fitch Ratings downgraded the company’s national credit rating by four notches, from AA+(bra) to A(bra), while maintaining a negative outlook. The agency cited the company’s failure to capture expected synergies following consolidation moves and projected negative operating cash flow over the next two years.
Quarterly results have kept investors on the defensive. The cash medical loss ratio rose to 77.2%, up two percentage points over 12 months. The number of beneficiaries fell by 1.8%.
In response to a request for comment, Hapvida said it “does not comment on market rumors or speculation.” The company added that, as stated in its third-quarter earnings report, it “maintains an ongoing agenda focused on operational efficiency and optimization of its healthcare network.” “Any transactions that are ultimately completed and deemed material will be disclosed to the market in accordance with applicable regulations.”
This article was translated from Valor Econômico using an artificial intelligence tool under the supervision of the Valor International editorial team to ensure accuracy, clarity, and adherence to our editorial standards. Read our Editorial Principles.
